AstraZeneca PLC (NASDAQ:AZN) Holdings Lowered by AdvisorNet Financial Inc

AdvisorNet Financial Inc decreased its stake in AstraZeneca PLC (NASDAQ:AZN) by 4.8% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 21,314 shares of the company’s stock after selling 1,065 shares during the quarter. AdvisorNet Financial Inc’s holdings in AstraZeneca were worth $1,396,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also recently bought and sold shares of the stock. FMR LLC boosted its position in shares of AstraZeneca by 1.1% in the third quarter. FMR LLC now owns 23,117,447 shares of the company’s stock worth $1,801,080,000 after buying an additional 258,477 shares during the period. Franklin Resources Inc. boosted its position in AstraZeneca by 8.7% during the 3rd quarter. Franklin Resources Inc. now owns 19,122,675 shares of the company’s stock worth $1,492,649,000 after acquiring an additional 1,522,715 shares during the period. Fisher Asset Management LLC grew its stake in AstraZeneca by 5.3% during the 3rd quarter. Fisher Asset Management LLC now owns 10,480,160 shares of the company’s stock valued at $816,509,000 after acquiring an additional 524,175 shares in the last quarter. Clearbridge Investments LLC increased its holdings in shares of AstraZeneca by 5.8% in the 2nd quarter. Clearbridge Investments LLC now owns 3,403,748 shares of the company’s stock valued at $265,458,000 after purchasing an additional 186,010 shares during the period. Finally, Bank of Montreal Can lifted its position in shares of AstraZeneca by 109.6% in the third quarter. Bank of Montreal Can now owns 3,071,333 shares of the company’s stock worth $238,397,000 after purchasing an additional 1,605,758 shares in the last quarter. Hedge funds and other institutional investors own 20.35% of the company’s stock.

AstraZeneca Price Performance

NASDAQ AZN opened at $65.37 on Wednesday. The company has a 50 day moving average price of $65.98 and a two-hundred day moving average price of $74.69. AstraZeneca PLC has a 12-month low of $60.47 and a 12-month high of $87.68. The stock has a market capitalization of $202.69 billion, a PE ratio of 31.28, a price-to-earnings-growth ratio of 1.19 and a beta of 0.46. The company has a quick ratio of 0.71, a current ratio of 0.93 and a debt-to-equity ratio of 0.71.

AstraZeneca (NASDAQ:AZN) last released its quarterly earnings data on Tuesday, November 12th. The company reported $1.04 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.01 by $0.03. The business had revenue of $13.57 billion during the quarter, compared to analyst estimates of $13.08 billion. AstraZeneca had a net margin of 12.68% and a return on equity of 30.01%. AstraZeneca’s quarterly revenue was up 18.0% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.87 EPS. As a group, equities analysts predict that AstraZeneca PLC will post 4.11 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts recently commented on the stock. UBS Group raised shares of AstraZeneca from a “sell” rating to a “neutral” rating in a research report on Wednesday, November 20th. Deutsche Bank Aktiengesellschaft upgraded shares of AstraZeneca from a “sell” rating to a “hold” rating in a report on Wednesday, November 6th. Two equities research analysts have rated the stock with a hold rating, six have issued a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat, AstraZeneca presently has a consensus rating of “Buy” and an average target price of $89.75.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.